Fig. 6From: Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experienceOverall, patients who received targeted or immunotherapy agents had a longer PFS than those who received chemotherapy (19.3 vs 6.7 months, P = 0.053)Back to article page